Polymun Scientific Immunbiologische Forschung Gmbh

Apeiron Biologics Ag

Apotex Inc.

Robert Weik

Hans Loibner

Hermann W Katinger

Manfred Schuster

Evelyne Janzek-Hawlat

Bernhard Peball

Stefan Stranner

Thomas Hemetsberger

Bettina Wagner

Heinz Redl

Diethard Mattanovich

Renate Kunert

Jason Everett Dowd

Gabriela Stiegler

Hubertus Hohenblum

Stefan Naschberger

The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.

Method for producing ACE2 polypeptide

A method for purifying rHuEPO through the use of a multi-step filtration process which provides for a rHuEPO product having superior stability and shelf-life.

Enhanced liquid formulation stability of erythropoietin alpha through purification processing

The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein the recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least one, preferably two or more, lysine amine residues and/or the N-terminal amino acid of the fusion protein are carbamoylated. The carbamoylated EPO-Fc fusion proteins of the present invention having a reduced hematopoietic activity whereas the tissue regenerative activity, i.e. the nerve cell regenerative activity remains unaltered or is even enhanced as compared to unmodified EPO-Fc fusion proteins. The invention further relates to a process for the manufacture of such fusion proteins and to pharmaceutical compositions containing them, as well as to the use of such fusion proteins and pharmaceutical compositions for medical therapy.

Carbamoylated EPO-Fc fusion proteins

Recombinant ACE2 polypeptide dimer

The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5

The present invention relates to a method for the manufacture and purification of recombinant trypsinogen and trypsin inand yeast, using high yield expression vectors with and without secretion leader sequences. The invention further relates to an improved method and apparatus for carrying out protein refolding specifically useful for processing trypsinogen that has accumulated intracellularly in the form of inclusion bodies.

Method for the manufacture of recombinant trypsin

Growing community of inventors

Hohe Wand-Stollhof, Austria

Robert Weik